THI appoints Sandford Smith MD
This article was originally published in Scrip
Tullis Health Investors, a family of funds and investments focused in emerging biopharmaceutical, medical device, medical service and other healthcare companies, has appointed Sandford Smith a managing director. Mr Smith has served on THI's advisory board since 2008, and was previously executive vice-president of Genzyme and president of Genzyme's international group.
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.